TXMD News and Press, TherapeuticsMD Inc. From 08/30/20

Most Popular Penny Stocks On Robinhood Right Now When it comes to penny stocks , Robinhood has become a popular platform to use among new traders. This gamified trading tool allows easy access to the stock market. Today, with so many new events influencing the way investors buy and sell, a mo...

Urban One (NASDAQ: UONE ) +85% . More news on: Urban One, Inc., Ovid Therapeutics Inc., RealNetworks, Inc., Stocks on the move, , Read more ...

Health Canada approves TherapeuticsMD (NASDAQ: TXMD ) and Knight Therapeutics' ( OTC:KHTRF )  Imvexxy for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). More news on: TherapeuticsMD, Inc., Knight Therapeutics In...

Robinhood investors apparently like pharmaceutical stocks , but a quick perusal of some of their favorites bring up three awful choices and one that might just turn out to be a good one. Buying stocks that are popular with a certain group of investors isn't inherently a bad idea, but it makes ...

It's become conventional wisdom on Wall Street that the Robinhood trading platform is a playground for young, inexperienced day traders chasing the quick buck -- so-called "dumb money" following the latest trend. Well, maybe experienced investors shouldn't be so quick to judge. A report by Gol...

TherapeuticsMD, Inc. (TXMD) Q2 2020 Earnings Conference Call August 6, 2020 08:30 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Robert Finizio - Chief Executive Officer James D’Arecca - Chief Financial Officer Dawn Halkuff - Chief Comme...

Image source: The Motley Fool. TherapeuticsMD, Inc.   (NASDAQ: TXMD) Q2 2020 Earnings Call Aug 06, 2020 , 8:30 a.m. ET Operator Continue reading

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Therapeutics MD (NASDAQ: TXMD ) : Q2 GAAP EPS of -$0.19 misses by $0.02 . More news on: TherapeuticsMD, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic - - ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period- - IMVEXXY® new prescriptions increased 33% for the eight...